secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0000950170-25-044353
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports FY2024 net loss $51.3M; Phase 3 epetraborole data expected 2Q25
--------------------------------------------------------------------------------

- Cash, equivalents, investments $88.6M at Dec 31, 2024; expected to fund operations through 2027.
- FY2024 net loss $51.3M vs $64.7M prior year; Q4 net loss $7.5M vs $16.9M.
- Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease due 2Q25.
- Phase 1 trial of AN2-502998 for Chagas disease to start mid-2025 in healthy volunteers.
- First oncology candidate from boron chemistry platform on track to advance in 2H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/0000950170-25-044353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/antx-20250325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer